Sunesis Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies. The company is also developing SNS-510, which is in preclinical pharmacology studies for the treatment of solid tumor and hematologic malignancies; TAK-580, a pan-Raf inhibitor program that is in Phase 1 clinical trial for the treatment of pediatric low-grade glioma; and vosaroxin, a topoisomerase 2 inhibitor, which completed a Phase 3 trial in patients with relapsed or refractory acute myeloid leukemia.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone650-266-3500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$240,000.00
Profitability
Miscellaneous
Employees29
Next Earnings Date11/4/2019 (Estimated)
OptionableOptionable
Sunesis Pharmaceuticals (NASDAQ:SNSS) Frequently Asked Questions
What is Sunesis Pharmaceuticals' stock symbol?
Sunesis Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNSS."
How were Sunesis Pharmaceuticals' earnings last quarter?
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) posted its earnings results on Wednesday, August, 7th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating analysts' consensus estimates of ($0.10) by $0.01. View Sunesis Pharmaceuticals' Earnings History.
When is Sunesis Pharmaceuticals' next earnings date?
What price target have analysts set for SNSS?
3 analysts have issued 12-month target prices for Sunesis Pharmaceuticals' stock. Their predictions range from $1.50 to $6.00. On average, they expect Sunesis Pharmaceuticals' stock price to reach $3.75 in the next twelve months. This suggests a possible upside of 333.2% from the stock's current price. View Analyst Price Targets for Sunesis Pharmaceuticals.
What is the consensus analysts' recommendation for Sunesis Pharmaceuticals?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sunesis Pharmaceuticals in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Sunesis Pharmaceuticals.
What are Wall Street analysts saying about Sunesis Pharmaceuticals stock?
Here are some recent quotes from research analysts about Sunesis Pharmaceuticals stock:
- 1. HC Wainwright analysts commented, "Our $267 price target is derived from a risk-adjusted (does not include CMT or Sanfilippo A) DCF analysis and is based on: beta of 1.79, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 8.7%, and tax rate of 15% beginning in FY 2024." (6/17/2019)
- 2. According to Zacks Investment Research, "Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. It has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. It is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. " (5/15/2019)
Has Sunesis Pharmaceuticals been receiving favorable news coverage?
News coverage about SNSS stock has trended negative on Thursday, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Sunesis Pharmaceuticals earned a news impact score of -2.9 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for Sunesis Pharmaceuticals.
Who are some of Sunesis Pharmaceuticals' key competitors?
Some companies that are related to Sunesis Pharmaceuticals include Collegium Pharmaceutical (COLL), XBiotech (XBIT), Neptune Wellness Solutions (NEPT), CymaBay Therapeutics (CBAY), Verrica Pharmaceuticals (VRCA), Merus (MRUS), resTORbio (TORC), MediciNova (MNOV), Karuna Therapeutics (KRTX), DURECT (DRRX), Provention Bio (PRVB), Protagonist Therapeutics (PTGX), Corbus Pharmaceuticals (CRBP), Kadmon (KDMN) and Prothena (PRTA).
What other stocks do shareholders of Sunesis Pharmaceuticals own?
Who are Sunesis Pharmaceuticals' key executives?
Sunesis Pharmaceuticals' management team includes the folowing people:
- Mr. Dayton Misfeldt, Interim CEO & Director (Age 45)
- Mr. William P. Quinn, Sr. VP of Fin. & Corp. Devel. and CFO (Age 48)
- Mr. Daniel N. Swisher Jr., Strategic Advisor (Age 56)
- Mr. Gene C. Jamieson, VP of Technical Operations
- Dr. Judith A. Fox, Chief Scientific Officer
Who are Sunesis Pharmaceuticals' major shareholders?
Sunesis Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.15%), Samsara BioCapital LLC (2.91%), Balyasny Asset Management LLC (2.30%), Point72 Asset Management L.P. (1.93%), Wells Fargo & Company MN (1.85%) and BlackRock Inc. (1.08%). Company insiders that own Sunesis Pharmaceuticals stock include Aisling Capital Iv, Lp, Dayton Misfeldt, Mpm Oncology Impact Management and William P Quinn. View Institutional Ownership Trends for Sunesis Pharmaceuticals.
Which institutional investors are selling Sunesis Pharmaceuticals stock?
Which institutional investors are buying Sunesis Pharmaceuticals stock?
SNSS stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Point72 Asset Management L.P., BlackRock Inc., Wells Fargo & Company MN, Northern Trust Corp, Algert Global LLC and A.R.T. Advisors LLC. Company insiders that have bought Sunesis Pharmaceuticals stock in the last two years include Aisling Capital Iv, Lp, Dayton Misfeldt, Mpm Oncology Impact Management and William P Quinn. View Insider Buying and Selling for Sunesis Pharmaceuticals.
How do I buy shares of Sunesis Pharmaceuticals?
Shares of SNSS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Sunesis Pharmaceuticals' stock price today?
One share of SNSS stock can currently be purchased for approximately $0.8656.
How big of a company is Sunesis Pharmaceuticals?
Sunesis Pharmaceuticals has a market capitalization of $96.36 million and generates $240,000.00 in revenue each year. The biopharmaceutical company earns $-26,610,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis. Sunesis Pharmaceuticals employs 29 workers across the globe.View Additional Information About Sunesis Pharmaceuticals.
What is Sunesis Pharmaceuticals' official website?
How can I contact Sunesis Pharmaceuticals?
Sunesis Pharmaceuticals' mailing address is 395 OYSTER POINT BOULEVARD SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-266-3500 or via email at [email protected]
MarketBeat Community Rating for Sunesis Pharmaceuticals (NASDAQ SNSS)
MarketBeat's community ratings are surveys of what our community members think about Sunesis Pharmaceuticals and other stocks. Vote "Outperform" if you believe SNSS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNSS will underperform the S&P 500 over the long term. You may vote once every thirty days.
